ACAnne‐Marie Cleton‐Jansen

Anne‐Marie Cleton‐Jansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne‐Marie Cleton‐Jansen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data

    by Marieke L. Kuijjer, Halfdan Rydbeck, Stine H. Kresse, Emilie P. Buddingh, Ana B. Lid, Helene Roelofs, Horst Bürger, Ola Myklebost, Pancras C. W. Hogendoorn, Leonardo A. Meza‐Zepeda, et al.

    High‐grade osteosarcoma is a tumor with a complex genomic profile, occurring primarily in adolescents with a second peak at middle age. The extensive genomic alterations obscure the identification of genes driving tumorigenesis during osteosarcoma development. To identify such driver genes, we integrated DNA copy number profiles (Affymetrix SNP 6.0) of 32 diagnostic biopsies with 84 expression profiles (Illumina Human‐6 v2.0) of high‐grade osteosarcoma as compared with its putative progenitor cells, i.e., mesenchymal stem cells (n = 12) or osteoblasts (n = 3). In addition, we performed paired analyses between copy number and expression profiles of a subset of 29 patients for which both DNA and mRNA profiles were available. Integrative analyses were performed in Nexus Copy Number software and statistical language R. Paired analyses were performed on all probes detecting significantly differentially expressed genes in corresponding LIMMA analyses. For both nonpaired and paired analyses, copy number aberration frequency was set to >35%. Nonpaired and paired integrative analyses resulted in 45 and 101 genes, respectively, which were present in both analyses using different control sets. Paired analyses detected >90% of all genes found with the corresponding nonpaired analyses. Remarkably, approximately twice as many genes as found in the corresponding nonpaired analyses were detected. Affected genes were intersected with differentially expressed genes in osteosarcoma cell lines, resulting in 31 new osteosarcoma driver genes. Cell division related genes, such as MCM4 and LATS2, were overrepresented and genomic instability was predictive for metastasis‐free survival, suggesting that deregulation of the cell cycle is a driver of osteosarcomagenesis.


  • An osteosarcoma zebrafish model implicates Mmp‐19 and Ets‐1 as well as reduced host immune response in angiogenesis and migration

    by Alexander B Mohseny, Wei Xiao, Ralph Carvalho, Herman P Spaink, Pancras Cw Hogendoorn, Anne‐Marie Cleton‐Jansen

    About 40% of osteosarcoma patients die of metastases. Novel strategies to improve treatment of metastatic patients require a better understanding of the processes involved, like angiogenesis, migration, and the immune response. However, the rarity of osteosarcoma and its heterogeneity make this neoplasm difficult to study. Recently we reported malignant transformation of mouse mesenchymal stem cells (MSCs) which formed osteosarcoma upon transplantation into mice. Here we studied these cells in zebrafish embryos and found that transformed MSCs induced angiogenesis and migrated through the bodies of the embryos, but this was never observed with non‐transformed normal MSCs (progenitors of the transformed MSCs). Whole genome expression analysis of both the cells and the host showed that angiogenesis and migration‐related genes matrix metalloproteinase 19 (Mmp‐19) and erythroblastosis virus E26 oncogene homologue 1 (Ets‐1) were overexpressed in transformed MSCs compared to normal MSCs. Investigating the host response, embryos injected with transformed MSCs showed decreased expression of immune response‐related genes, especially major histocompatibility complex class 1 (mhc1ze) , as compared to embryos injected with normal MSCs. These findings contribute to the identification of genetic events involved in angiogenesis, migration, and host response providing targets as well as an appropriate model for high‐throughput drug screens. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Different mechanisms of chromosome 16 loss of heterozygosity in well‐ versus poorly differentiated ductal breast cancer

    by Anne‐Marie Cleton‐Jansen, Horst Buerger, Natalja ter Haar, Katja Philippo, Marc J. van de Vijver, Werner Boecker, Vincent T. H. B. M. Smit, Cees J. Cornelisse

    Loss of heterozygosity (LOH) at the long arm of chromosome 16 is a frequent genetic alteration in breast cancer. It can occur by physical loss of part of or the entire chromosomal arm, resulting in a decrease in copy number or loss followed by mitotic recombination. Comparative genomic hybridization (CGH) demonstrated that well‐differentiated breast tumors showed significantly more physical loss of 16q than did poorly differentiated ones and that this difference was already discernable in the preinvasive stage. However, polymorphic markers detected no difference in the frequency of 16q LOH between invasive tumors of different histological grade. Here, by combining data on LOH (n = 52), fluorescence in situ hybridization (n = 18) with chromosome 16–specific probes, and CGH (n = 34), we show a preference in well‐differentiated grade I tumors for physical loss of chromosome arm 16q, whereas in poorly differentiated grade III tumors LOH is accompanied by mitotic recombination. This clarifies the discrepancies observed between CGH and LOH for 16q in breast cancer. These different somatic genetic mechanisms may reflect the presence of multiple tumor suppressor genes that are the target of LOH at chromosome arm 16q.